December 13, 2019

X-rays shed light on how anti-asthmatic drugs work

A new study uncovers how a critical protein binds to drugs used to treat asthma and other inflammatory diseases.

By Jennifer Huber

By studying the crystal structure of an important protein when it was bound to two drugs widely prescribed to treat asthma, an international team of scientists has discovered unique binding and signaling mechanisms that could lead to the development of more effective treatments for asthma and other inflammatory diseases.

The protein, called cysteinyl leukotriene receptor type 1 (CysLT1R), controls the dilation and inflammation of bronchial tubes in the lungs. It is therefore one of the primary targets for anti-asthma drugs, including the two drugs studied: zafirlukast, which acts on inflammatory cells in the lungs, and pranlukast, which reduces bronchospasms due to allergic reactions.

Anti-asthmatic drugs
Using X-rays, researchers uncovered details about two drugs widely prescribed to treat asthma: pranlukast (shown up top) and zafirlukast (shown beneath). Their results revealed major differences between how the two drugs attached to the binding site of the receptor protein. In comparison to pranlukast, the zafirlukast molecule jammed open the entrance gate of protein’s binding site into a much wider configuration. (10.1126/sciadv.aax2518)

Using the Linac Coherent Light Source (LCLS) X-ray free-electron laser at the Department of Energy’s SLAC National Accelerator Laboratory, the team bombarded tiny crystals of CysLT1R-zafirlukast with X-ray pulses and measured its structure. They also used X-rays from the European Synchrotron Radiation Facility in Grenoble, France to collect data about CysLT1R-pran crystals. They published their findings in October in Science Advances.

The researchers gained a new understanding of how CysLT1R interacts with these anti-asthma drugs, observing surprising structural features and a new activation mechanism. For example, the study revealed major differences between how the two drugs attached to the binding site of the protein. In comparison to pranlukast, the zafirlukast molecule jammed open the entrance gate of CysLT1R’s binding site into a much wider configuration. This improved understanding of the protein suggests a new rationale for designing more effective anti-asthma drugs.

The study was performed by a collaboration of researchers at SLAC; Moscow Institute of Physics and Technology, Russia; University de Sherbrooke, Canada; University of Southern California; Research Center Juelich, Germany; Universite Grenoble Alpes-CEA-CNRS, France; Czech Academy of Sciences, Czech Republic; and Arizona State University. Crystallography data collection of CysLT1R-pran crystals was performed at the European Synchrotron Radiation Facility in Grenoble, France.

Citation: Aleksandra Luginina et al.Science Advances, 09 October 2019 (10.1126/sciadv.aax2518).

For questions or comments, contact the SLAC Office of Communications at communications@slac.stanford.edu.


SLAC is a vibrant multiprogram laboratory that explores how the universe works at the biggest, smallest and fastest scales and invents powerful tools used by scientists around the globe. With research spanning particle physics, astrophysics and cosmology, materials, chemistry, bio- and energy sciences and scientific computing, we help solve real-world problems and advance the interests of the nation.

SLAC is operated by Stanford University for the U.S. Department of Energy’s Office of Science. The Office of Science is the single largest supporter of basic research in the physical sciences in the United States and is working to address some of the most pressing challenges of our time. For more information, visit energy.gov/science.

Dig Deeper

Related stories

Press Release

With up to a million X-ray flashes per second, 8,000 times more than its predecessor, it transforms the ability of scientists to explore atomic-scale...

LCLS-II first light
News Brief

They aim to help society respond ten times faster with treatments for future disease outbreaks.

This is a portrait photograph of SSRL scientist Aina Cohen.
News Feature

In our rapidly changing world, plants must adapt to new environments or die. Ritimukta Sarangi discusses how researchers and users at SSRL are tackling...

A graphic illustrating a plant and the many kinds of interactions it has with its environment.
Press Release

With up to a million X-ray flashes per second, 8,000 times more than its predecessor, it transforms the ability of scientists to explore atomic-scale...

LCLS-II first light
News Brief

They aim to help society respond ten times faster with treatments for future disease outbreaks.

This is a portrait photograph of SSRL scientist Aina Cohen.
News Feature

In our rapidly changing world, plants must adapt to new environments or die. Ritimukta Sarangi discusses how researchers and users at SSRL are tackling...

A graphic illustrating a plant and the many kinds of interactions it has with its environment.
News Feature

Bringing ultrafast physics to structural biology has revealed the coordinated dance of molecules in unprecedented clarity, which could aid in the design of new...

molecular control
News Feature

The results should further our understanding of similar reactions with vital roles in chemistry, such as the production of vitamin D in our bodies.

UED transition state
Press Release

After decades of effort, scientists have finally seen the process by which nature creates the oxygen we breathe using SLAC’s X-ray laser.

Photosystem II